

# Tomas Tesar

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2405699/publications.pdf>

Version: 2024-02-01

58  
papers

1,742  
citations

516710

16  
h-index

276875

41  
g-index

58  
all docs

58  
docs citations

58  
times ranked

2252  
citing authors

#	ARTICLE	IF	CITATIONS
1	Antimicrobial Drug Use and Resistance in Europe. <i>Emerging Infectious Diseases</i> , 2008, 14, 1722-1730.	4.3	404
2	Self-medication with Antimicrobial Drugs in Europe. <i>Emerging Infectious Diseases</i> , 2006, 12, 452-459.	4.3	292
3	Comparison of Outpatient Systemic Antibacterial Use in 2004 in the United States and 27 European Countries. <i>Clinical Infectious Diseases</i> , 2007, 44, 1091-1095.	5.8	196
4	European Surveillance of Antimicrobial Consumption (ESAC): quality indicators for outpatient antibiotic use in Europe. <i>Quality and Safety in Health Care</i> , 2007, 16, 440-445.	2.5	154
5	Antibiotic use in ambulatory care in Europe (ESAC data 1997-2002): trends, regional differences and seasonal fluctuations. <i>Pharmacoepidemiology and Drug Safety</i> , 2007, 16, 115-123.	1.9	91
6	Systemic Measures and Legislative and Organizational Frameworks Aimed at Preventing or Mitigating Drug Shortages in 28 European and Western Asian Countries. <i>Frontiers in Pharmacology</i> , 2018, 8, 942.	3.5	70
7	Pricing and Reimbursement of Biosimilars in Central and Eastern European Countries. <i>Frontiers in Pharmacology</i> , 2017, 8, 288.	3.5	50
8	Consumption of antibiotics in the community, European Union/European Economic Area, 1997-2017. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, ii7-ii13.	3.0	40
9	Consumption of quinolones in the community, European Union/European Economic Area, 1997-2017. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, ii37-ii44.	3.0	34
10	Pharmaceutical Regulation in Central and Eastern European Countries: A Current Review. <i>Frontiers in Pharmacology</i> , 2017, 8, 892.	3.5	27
11	Decreasing and stabilising trends of antimicrobial consumption and resistance in <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> in segmented regression analysis, European Union/European Economic Area, 2001 to 2018. <i>Eurosurveillance</i> , 2019, 24, .	7.0	25
12	The effectiveness of daily SMS reminders in pharmaceutical care of older adults on improving patients' adherence to antihypertensive medication (SPPA): study protocol for a randomized controlled trial. <i>Trials</i> , 2017, 18, 334.	1.6	24
13	Patient Access, Unmet Medical Need, Expected Benefits, and Concerns Related to the Utilisation of Biosimilars in Eastern European Countries: A Survey of Experts. <i>BioMed Research International</i> , 2018, 2018, 1-9.	1.9	23
14	Reimbursement Legislations and Decision Making for Orphan Drugs in Central and Eastern European Countries. <i>Frontiers in Pharmacology</i> , 2019, 10, 487.	3.5	22
15	Patient-related characteristics associated with non-persistence with statin therapy in elderly patients following an ischemic stroke. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 201-207.	1.9	19
16	Consumption of tetracyclines, sulphonamides and trimethoprim, and other antibacterials in the community, European Union/European Economic Area, 1997-2017. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, ii45-ii59.	3.0	17
17	Consumption of penicillins in the community, European Union/European Economic Area, 1997-2017. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, ii14-ii21.	3.0	17
18	Consumption of macrolides, lincosamides and streptogramins in the community, European Union/European Economic Area, 1997-2017. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, ii30-ii36.	3.0	16

#	ARTICLE	IF	CITATIONS
19	Quality appraisal of antibiotic consumption in the community, European Union/European Economic Area, 2009 and 2017. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, ii60-ii67.	3.0	15
20	The transferability of health technology assessment: the European perspective with focus on central and Eastern European countries. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2020, 20, 321-330.	1.4	14
21	Consumption of antibiotics in the community, European Union/European Economic Area, 1997-2017: data collection, management and analysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, ii2-ii6.	3.0	14
22	Consumption of cephalosporins in the community, European Union/European Economic Area, 1997-2017. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, ii22-ii29.	3.0	14
23	Comparative Analysis of Legislative Requirements About Patients' Access to Biotechnological Drugs for Rare Diseases in Central and Eastern European Countries. <i>Frontiers in Pharmacology</i> , 2018, 9, 795.	3.5	13
24	The implications of external price referencing on pharmaceutical list prices in Europe. <i>Health Policy and Technology</i> , 2018, 7, 243-250.	2.5	13
25	INTRODUCTION OF HEALTH TECHNOLOGY ASSESSMENT FOR MEDICINES IN SLOVAKIA. <i>International Journal of Technology Assessment in Health Care</i> , 2017, 33, 345-349.	0.5	12
26	Change-points in antibiotic consumption in the community, European Union/European Economic Area, 1997-2017. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, ii68-ii78.	3.0	12
27	Factors Influencing Non-Persistence with Antiplatelet Medications in Elderly Patients After Ischaemic Stroke. <i>Drugs and Aging</i> , 2016, 33, 365-373.	2.7	10
28	Patient-Associated Characteristics Influencing the Risk for Non-Persistence with Statins in Older Patients with Peripheral Arterial Disease. <i>Drugs and Aging</i> , 2019, 36, 863-873.	2.7	10
29	Analysing the trend over time of antibiotic consumption in the community: a tutorial on the detection of common change-points. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, ii79-ii85.	3.0	10
30	Health technology assessment and reimbursement policy for oncology orphan drugs in Central and Eastern Europe. <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 277.	2.7	9
31	Potential Cost-Savings From the Use of the Biosimilars in Slovakia. <i>Frontiers in Public Health</i> , 2020, 8, 431.	2.7	8
32	How Changes in Reimbursement Practices Influence the Financial Sustainability of Medicine Policy: Lessons Learned from Slovakia. <i>Frontiers in Pharmacology</i> , 2019, 10, 664.	3.5	7
33	Development of a core evaluation framework of value-added medicines: report 1 on methodology and findings. <i>Cost Effectiveness and Resource Allocation</i> , 2021, 19, 57.	1.5	7
34	Non-Persistence With Antiplatelet Medications Among Older Patients With Peripheral Arterial Disease. <i>Frontiers in Pharmacology</i> , 2021, 12, 687549.	3.5	6
35	Age-Related Differences in Non-Persistence with Statin Treatment in Patients after a Transient Ischaemic Attack. <i>Clinical Drug Investigation</i> , 2017, 37, 1047-1054.	2.2	5
36	Development of a core evaluation framework of value-added medicines: report 2 on pharmaceutical policy perspectives. <i>Cost Effectiveness and Resource Allocation</i> , 2021, 19, 42.	1.5	5

#	ARTICLE	IF	CITATIONS
37	Development of transferability guidance for integrated care models with special focus on Central and Eastern European countries. <i>Croatian Medical Journal</i> , 2020, 61, 252-259.	0.7	5
38	Implementation of coverage with evidence development schemes for medical devices: A decision tool for late technology adopter countries. <i>Health Economics (United Kingdom)</i> , 2022, , .	1.7	5
39	The Impact of Reimbursement Practices on the Pharmaceutical Market for Off-Patent Medicines in Slovakia. <i>Frontiers in Pharmacology</i> , 2021, 12, 795002.	3.5	5
40	Non-persistence with antiplatelet therapy in elderly patients after a transient ischemic attack. <i>Ageing Clinical and Experimental Research</i> , 2017, 29, 1121-1127.	2.9	4
41	Outpatient use of systemic antibiotics in Croatia. <i>International Journal of Clinical Pharmacy</i> , 2006, 28, 39-40.	1.4	3
42	The impact of implemented regulations on biosimilars in Slovakia. <i>Health Policy and Technology</i> , 2019, 8, 408-413.	2.5	3
43	Reinitiation and Subsequent Discontinuation of Antiplatelet Treatment in Nonpersistent Older Patients with Peripheral Arterial Disease. <i>Biomedicines</i> , 2021, 9, 1280.	3.2	3
44	Cost-Utility Analysis of Heberprot-P as an Add-on Therapy to Good Wound Care for Patients in Slovakia with Advanced Diabetic Foot Ulcer. <i>Frontiers in Pharmacology</i> , 2017, 8, 946.	3.5	2
45	Gender Differences in Non-Persistence with Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers among Older Hypertensive Patients with Peripheral Arterial Disease. <i>Biomedicines</i> , 2022, 10, 1479.	3.2	2
46	Mapping of The Biosimilar Drug Policy in 10 Central Eastern European Countries. <i>Value in Health</i> , 2016, 19, A504-A505.	0.3	1
47	Non-Adherence to Statin Treatment in Older Patients with Peripheral Arterial Disease Depending on Persistence Status. <i>Biomedicines</i> , 2020, 8, 378.	3.2	1
48	Consumption of Antibacterials for Systemic Use in Slovakia: A National Study and the Quality Indicators for Outpatient Antibiotic Use. <i>Antibiotics</i> , 2021, 10, 1180.	3.7	1
49	Retrospective study assessing efficacy and safety of left atrial appendage occlusion. <i>Bratislava Medical Journal</i> , 2020, 121, 609-618.	0.8	1
50	Adherence to Antiplatelet Medications among Persistent and Non-Persistent Older Patients with Peripheral Arterial Disease. <i>Biomedicines</i> , 2021, 9, 1800.	3.2	1
51	PCV46 COST-ANALYSIS OF HYPERCHOLESTEROLEMIATREATMENTS WITHIN THE SLOVAK PHARMACEUTICAL MARKET. <i>Value in Health</i> , 2005, 8, A102-A103.	0.3	0
52	PDB66 HEALTH CARE UTILISATION AND EXPENDITURES ASSOCIATED WITH TREATMENTS OF DIABETES MELLITUS WITHIN THE SLOVAK REPUBLIC. <i>Value in Health</i> , 2008, 11, A236-A237.	0.3	0
53	PIN74 Cost Savings Due to Antibiotic Prescription Related to Quick C-Reactive Protein Testing. <i>Value in Health</i> , 2012, 15, A398-A399.	0.3	0
54	Implication Of External Price Referencing On Pharmaceutical List Prices In Europe. <i>Value in Health</i> , 2016, 19, A444.	0.3	0

#	ARTICLE	IF	CITATIONS
55	Utilization of Lipid-Lowering Drugs in Slovakia: Comparison of Data from Different Sources. Value in Health, 2017, 20, A626-A627.	0.3	0
56	Factors Associated with Reinitiation of Statin Treatment in Older Patients with Peripheral Arterial Disease. Drugs and Aging, 2020, 37, 595-604.	2.7	0
57	PNS77 Transferring Health Technology Assessments from EARLY Adopter to Late Adopter Countries: Recommendations for the Implementation of CED Schemes in Central and Eastern European Countries. Value in Health, 2021, 24, S187.	0.3	0
58	PNS108 Proposal for a Core Evaluation Framework of Value Added Medicines. Value in Health, 2020, 23, S659-S660.	0.3	0